Skip to main content
Midas Edge

Avalo Therapeutics, Inc.

For the period ended Dec 31, 2024. Filed Mar 20, 2025.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 20, 2025

AVTX$7.27+4.9%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Table of Contents

Page
PART Iii
Item 1. Business1
Item 1A. Risk Factors12
Item 1B. Unresolved Staff Comments44
Item 1C. Cybersecurity44
Item 2. Properties45
Item 3. Legal Proceedings45
Item 4. Mine Safety Disclosures46
PART II47
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities47
Item 6. Reserved48
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations49
Item 7A. Quantitative and Qualitative Disclosures About Market Risk58
Item 8. Financial Statements and Supplementary Data58
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure58
Item 9A. Controls and Procedures58
Item 9B. Other Information59
Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspection59
PART III60
Item 10. Directors, Executive Officers and Corporate Governance60
Item 11. Executive Compensation64
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters72
Item 13. Certain Relationships and Related Transactions, and Director Independence75
Item 14. Principal Accountant Fees and Services77
PART IV78
Item 15. Exhibits; Financial Statement Schedules78

i

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.